Trial Profile
Dose Finding Study for Reversal of Vecuronium-induced Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Aug 2020
Price :
$35
*
At a glance
- Drugs Neostigmine (Primary) ; Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 09 Aug 2020 Status changed from active, no longer recruiting to completed.
- 11 Sep 2018 New trial record